Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorFujian Medical University
About this trial
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.
Eligibility criteria
Qualifiers
Age 18-65 years.
Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.
Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.
No radiologic lymph-node metastasis on contralateral side.
Disqualifiers
Extrathyroidal extension, gross nodal or distant metastasis.
Prior neck surgery, prior RFA/ethanol injection, or neck irradiation.
Pregnancy or lactation.
Serious comorbidities precluding anesthesia or follow-up.
Trial design
Treatments tested in this trial
- Endoscopic Hemithyroidectomy with Central-Neck Dissection
- Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov